$225 million invested in research since inception

310 research projects funded since 1998, including 26 clinical trials

PARTNERSHIPS WITH 75 academic institutions
Driven to action by Marc Lustgarten’s devastating diagnosis and lack of treatment options in 1998, the Lustgarten Foundation is turning research progress into solutions in the clinic and providing the potential for more tomorrows for patients diagnosed today.

Lustgarten-funded science has been a driving force in every major advancement in pancreatic cancer research due to the Foundation’s visionary investment in basic, foundational science.

The Lustgarten Foundation funds the world’s preeminent pancreatic cancer researchers, leading the pursuit of bold and innovative science toward earlier detection, better treatments and a curable disease.
Recent advances in the diagnosis and treatment of pancreatic cancer have been possible because of pioneering studies into the underlying genetic, molecular and cellular processes of pancreatic cancer progression, led by the Lustgarten Foundation and powered by you. While 2021 continued to be a uniquely challenging year for us all, we hope you and your loved ones continue to be safe and well. If you or your family have been ill or otherwise negatively impacted by COVID-19, we wish you good health and brighter days ahead. We are in awe of the strength and determination of the pancreatic cancer community, which is only bolstering our resolve to accelerate collaborative and innovative research to save lives.

Since the Lustgarten Foundation took up the challenge of curing pancreatic cancer in 1998, the five-year survival rate has more than doubled to 11%. Good news? Absolutely! Good enough? Absolutely not! But, through Lustgarten’s early and foundational support, the field’s boldest and most innovative thinkers are transforming our understanding of and approach to the disease.

Though remaining relatively rare at only 3% of all cancers, research predicts pancreatic cancer will become the second deadliest cancer in the United States by 2030, second only to lung cancer. Presenting an emerging threat, this data is a stark reminder that much work lies ahead to improve outcomes for pancreatic cancer patients.

The Lustgarten Foundation’s commitment is steadfast, and you are as essential to advancing research as every investigator we fund. Critical breakthroughs would not be possible without Lustgarten’s dedicated community of donors, volunteers, fundraisers and corporate partners. Your investments provide Lustgarten researchers with the sustained support essential for innovation. Your contributions are the foundation of critical, multi-year programs that continue to illuminate this deadly disease and supply concrete insights, data, and progress.

Led by the vision of our impassioned founders and highly motivated Board of Directors, we—and our deep bench of investigators—will continue to forge ahead in the face of ongoing challenges. Challenges the Lustgarten Foundation is uniquely prepared and positioned to meet. Your persistence inspires us daily; your continued commitment to our mission gives us the capacity to transform possibilities into realities and wield the power of research to extend lives.

Your unwavering support has enabled us to invest nearly $225 million in high-risk, high-reward science to launch clinical trials; fund new grant programs; expand existing collaborations, partnerships, and research initiatives; and take steps to honor our commitment to diversity, equity, and inclusion. Community is power and we are stronger because of you.
Thanks to you the Lustgarten Foundation is the linchpin of the pancreatic cancer community. Because of you, we are giving patients more time with their loved ones and more hope than ever before. We look forward to sharing our research progress with you throughout 2022.

WITH GRATITUDE,

Andrew Lustgarten  
Chairman of the Board of Directors, Lustgarten Foundation;  
President and CEO, MSG Sports;  
President, MSG Entertainment

Linda Tantawi  
CEO, Lustgarten Foundation

Kerri Kaplan  
President, Lustgarten Foundation

100% of contributions fund pancreatic cancer research
Pancreatic cancer accounts for just 3% of cancers diagnosed in the United States each year, yet it is on track to become the second leading cause of cancer-related deaths by 2030. To change this trajectory, Lustgarten's research strategy is focused on the areas of greatest need for patients: earlier detection, new drug development and personalized medicine. To ensure research progress turns into clinical advances, we concentrate on the transition from the bench to the bedside—translating our understanding of the underlying biology of pancreatic cancer into clinical testing opportunities and realities for patients.
We’re not done learning. Until every single patient that I’ve ever seen, or am going to see, can tell me they don’t have metastatic pancreatic cancer anymore, that they feel good, that they’re living a normal life, I don’t think we’re done. But what I will tell you is that more than ever, I am optimistic that we’re making progress.

– Elizabeth Jaffee, MD, Chief Medical Advisor
The October 8, 2021, edition of the scientific journal Cancer Prevention Research included preliminary data from the GENERATE Study (www.generatestudy.org). Funded through the Pancreatic Cancer Collective (PCC), Lustgarten’s strategic collaboration with Stand Up To Cancer (SU2C), the study is investigating the potential impact of improved genetic testing and cancer prevention for those with a first- or second-degree relative with pancreatic cancer. Inherited (genetic) mutations cause approximately 10% of pancreatic cancer cases. GENERATE shows promise for the use of remote tools, such as at-home testing and virtual genetic education and support to reach those at increased risk regardless of proximity to comprehensive cancer treatment facilities.

The Lustgarten Lab at Johns Hopkins is working to discover pancreatic cancer at an earlier stage when patients may be surgical candidates. Led by Bert Vogelstein, MD, Lustgarten-funded scientists developed CancerSEEK, a powerful blood test capable of detecting the early presence of multiple cancers, including pancreatic cancer, and identifying where in the body the cancer began. In 2021, Exact Sciences acquired the rights to CancerSEEK and is preparing to initiate an 80,000-person registration trial as a step toward FDA approval.
“The Lustgarten Foundation was one of the first private foundations to recognize the importance of early detection, and to recognize that prevention is better than a cure whenever it can be practiced. They were way ahead of the crowd for a long time as the only foundation convinced this was one of the major ways forward.”
Pancreatic cancer is often diagnosed after it has already metastasized; pancreatic cancer patients do not have time to waste on treatments unlikely to help them. The Lustgarten Foundation is driven to continue to innovate, lead and push for progress, identifying new drug targets and expediting preclinical and clinical testing of new drugs and drug combinations to help as many pancreatic cancer patients as possible.

The Lustgarten Laboratory at Dana-Farber Cancer Institute, led by Brian Wolpin, MD, MPH, is a critical hub for this type of scientific discovery, advancing research from the laboratory to the clinic, initiating scientifically-driven clinical trials, identifying new approaches to early detection and analyzing pancreatic cancer subtypes.

Dr. Wolpin's research is complemented by the Clinical Accelerator Initiative (CAI), which is bringing the work from the lab to the clinic even faster—increasing the number and pace of new clinical trials. The CAI shortens the time from clinical trial concept to launch using a Lustgarten-developed process based on the best available science and employing cutting-edge biomarkers. These “smarter” clinical trials will generate large volumes of data scientists can use now and in the future. Even if a trial fails, the data will help inform and improve future clinical trials and expedite new treatments. By testing drugs developed based on insights specifically from pancreatic cancer patients, doctors will be armed with more potentially life-saving treatment options to offer their patients at every stage of the disease.

In 2021, the Foundation approved $6.1 million to fund four CAI studies. Three of these clinical studies test immunotherapy treatments—looking into ways the body’s own immune system can work to combat pancreatic cancer so more patients have better outcomes. Two studies, one for metastatic patients and one for patients in the neoadjuvant (pre-surgery) setting, examine new combinations of vaccines and drugs targeting the immune system to determine if they can prevent tumors from becoming resistant to immune therapies. The third study tests a new combination of drugs to simultaneously activate the T cells (a type of immune cell) and block the inhibitory signals from the tumor.
Immunotherapy is effective in treating multiple cancer types. Renowned immunologist Elizabeth Jaffee, MD, is the Foundation’s Chief Medical Advisor and Director of the second Lustgarten Laboratory at Johns Hopkins. Dr. Jaffee’s focus is on developing new approaches to bring the benefits of immunotherapy to pancreatic cancer. At the Lustgarten Laboratory at the Massachusetts Institute of Technology (MIT), Tyler Jacks, PhD, also is focused on the immune system. He and his team are merging technology and engineering to study the genetic events contributing to cancer development and examining the immune responses to the disease using molecular profiling to identify tumor mutations.

The fourth CAI-funded study is a phase II trial testing a novel drug combination to prevent chemotherapy resistance in metastatic pancreatic cancer patients. Led by Colin Weekes, MD, PhD, Massachusetts General Hospital, the study is focused on extending the efficacy of the standard-of-care treatment FOLFIRINOX. This study will test a novel combination (Losartan and 9-ING-41) in patients taking FOLFIRINOX to determine if this combination can help to prevent chemotherapy resistance.

The Therapeutics-Focused Research Program will deepen the scientific and medical community’s understanding of the causes of pancreatic cancer and develop a robust pipeline of potential new treatment options. This $11.2 million grant promotes collaboration across labs and is expected to identify new therapeutic approaches and drug targets. Fifty proposals underwent rigorous review by external pancreatic cancer experts; 10 projects were selected for funding, focusing on four key areas of pancreatic cancer biology:

- Discovering how the stroma—the supportive tissue surrounding the pancreatic tumor—may block treatments from reaching the tumor and design therapies to penetrate the barrier
- Understanding and discovering how to block inflammatory signals in response to environmental triggers that can lead to pancreatic cancer and other pancreatic diseases
- Determining ways to stop tumor cell growth by blocking the abnormal metabolic pathways used by pancreatic cancer cells
- Preventing the spread—or metastasis—of cancer by isolating metastatic triggers in cancer cells and the stroma
Lustgarten’s Commitment to Equity, Diversity and Inclusion

Solving the complex problem of pancreatic cancer requires diversity of thought, education, training, background and experience to move progress forward. Our commitment to ensuring equity, diversity and inclusion—across Lustgarten-funded research and the scientists we support—is foundational to our mission to cure pancreatic cancer.

Supporting distinguished early-career scientists helps ensure their continued commitment to studying pancreatic cancer. The Lustgarten Foundation created two Career Development Awards to increase the number of early-career women and underrepresented scientists receiving funding for pancreatic cancer research. The awards support investigators committed to increasing our understanding and treatment of this disease. The awards honor the lives and legacies of two trailblazing Americans lost to pancreatic cancer—Justice Ruth Bader Ginsburg and Congressman John Robert Lewis. Each recipient is awarded a 3-year, $300,000 grant for their pancreatic cancer research.

Inaugural recipients:

Career Development Award in honor of Ruth Bader Ginsburg
Dannielle Engle, PhD, an assistant professor at the Salk Institute for Biological Studies, is investigating the role of pancreatitis and inflammation in the formation of pancreatic cancer.

Career Development Award in honor of John Robert Lewis
Avery D. Posey Jr., PhD, an assistant professor in the Perelman School of Medicine at the University of Pennsylvania, is continuing his research to increase immune system effectiveness at attacking pancreatic cancer. Dr. Posey was the lead presenter at Lustgarten’s Juneteenth webinar.

The program is supported by Bristol Myers Squibb and is administered by the American Association for Cancer Research (AACR).

Understanding the Impact of Race on Pancreatic Cancer

A new retrospective research project, Understanding the Impact of Race on Pancreatic Cancer, led by Howard Crawford, PhD, Scientific Director, Henry Ford Pancreatic Cancer Center, is analyzing tumor samples to determine if genomic and cellular differences might account for the higher rates and poorer outcomes of pancreatic cancer in Black Americans. Data estimates Black Americans have a 20% higher incidence rate than white Americans. The study is funded in part through a grant from Bristol Myers Squibb.
PERSONALIZED MEDICINE
Lustgarten’s Chief Scientist, David Tuveson, MD, PhD, leads the Lustgarten Laboratory at Cold Spring Harbor Laboratory, designing new models of the disease and discovering novel therapeutic and diagnostic platforms to bring new options to patients more rapidly. Dr. Tuveson was the first scientist to develop a pancreatic cancer organoid—a 3D cell culture system that reproduces a patient’s tumor. Researchers can repeatedly test the effectiveness of different drugs on the organoid to accurately predict how a patient will respond to various therapies, offering the hope of personalized cancer treatments.

PREDICTING TUMOR RESPONSE
Pancreatic cancer researchers from the United States and Canada are conducting the PASS-01 trial to predict which of the two standard-of-care treatment regimens might work best for individual pancreatic cancer patients based on the molecular traits of their tumors. The study includes an in-depth analysis of each participant’s tumor and response to therapy. Researchers are using organoids to analyze the tumor’s biology and drug sensitivity and apply this data to determine if organoids can predict the most effective treatment for each patient. If successful, this trial can pave the way for organoids to personalize therapies for metastatic pancreatic cancer patients.

The organoid work for the PASS-01 trial is being conducted at the state-of-the-art organoid testing facility at Cold Spring Harbor Laboratory, where researchers are growing and testing organoids for trial participants. Additionally, this organoid research will help determine if neither of the standard-of-care options is likely to help a patient, so a patient’s doctor can pursue a different avenue of treatment.

The PASS-01 trial is funded through the Gail V. Coleman and Kenneth M. Bruntel Organoids for Personalized Therapy Grant.

“When the cancer migrates, it’s hard for doctors to help patients. It causes more symptoms in patients, but it’s not game over. It just means a different game. It means we have to approach patients differently.”
PANCREATIC CANCER COLLECTIVE (PCC)

To hasten the Foundation’s impact on pancreatic cancer research, the Lustgarten Foundation has collaborated with Stand Up To Cancer (SU2C) since 2012. The PCC has conducted nearly 30 clinical trials led by more than 400 research investigators at 70 institutions. The PCC supports groundbreaking progress in identifying new treatments for pancreatic cancer and improving patient outcomes. Four projects supported by the Collective’s "New Therapies Challenge" grants received a second round of funding to advance potential treatments into clinical trials. The PCC also awarded two grants for computational studies using artificial intelligence to analyze medical records as well as clinical and molecular data from patients. From data collected, researchers will create risk models and develop biomarkers to identify people in the general population who may be at high risk for pancreatic cancer.

AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR)

The AACR is the world’s first and largest professional organization dedicated to advancing cancer research. We are proud to partner with the AACR to administer the Foundation’s Career Development Awards and the PCC grants. David Tuveson, MD, PhD, the Foundation’s Chief Scientist, is serving as the President of the AACR for the 2021–2022 term, leading approximately 48,000 members across 127 countries.

WORLD PANCREATIC CANCER COALITION (WPCC)

The Lustgarten Foundation was one of the first members of the World Pancreatic Cancer Coalition, which facilitates global collaboration between disease-focused organizations. The WPCC created World Pancreatic Cancer Day, which is celebrated annually in November.
Ed Moyer knows time is everything for pancreatic cancer patients. Like many others, Ed’s pancreatic cancer symptoms seemed to come out of the blue. He felt great on Christmas Day of 2018, but the next day he felt nauseous and had no appetite, and everything smelled awful to him.

Ed and his wife, Janet, had spent the holidays with their family in Virginia Beach, so Ed assumed he caught a bug or the flu from one of the kids there. It was fortunate he had a blood test at an urgent care center before heading home to Kansas. The test revealed he had elevated liver enzymes, which often indicate inflammation or damage to the cells in the liver. Back home, he underwent a battery of tests and scans, which revealed a small, malignant mass on the head of his pancreas.

It all happened so quickly. Ed’s first symptoms appeared on December 26th, and diagnosis was January 11th. Within those sixteen days, Ed turned 59. Despite this devastating diagnosis, Ed also had some things going in his favor: the love and strength of his family, the support and encouragement of his friends and colleagues, an incredible medical team and an open mind about participating in clinical research.

In February 2019, Ed joined a clinical study—a scientific investigation funded in part through your support of the Lustgarten Foundation. The study, directed by his doctors at Johns Hopkins, was designed to help patients like Ed. “My doctors recommended I participate in the clinical study first,” explained Ed. “I felt fortunate to have this option not only for myself, but to help advance research for future patients.”

Ed’s plan involved one treatment with immunotherapy and a vaccine to treat pancreatic cancer. He then had a Whipple surgery—a complex operation to remove the pancreas head, part of the small intestine, gallbladder and bile duct. Ed was relieved to be eligible for the Whipple surgery, as this procedure offers the best chance for long-term survival.

Following surgery, Ed had another round of the immunotherapy and vaccine treatment, six months of chemotherapy, and finally 10 monthly doses of the clinical study treatments again.

The clinical study and Ed’s treatment plan succeeded, and Ed’s latest CT scan continues to show no evidence of disease. As Ed’s experience demonstrates, research is fundamental to transforming pancreatic cancer into a curable disease.
COMMUNITY IS POWER
Northwell Health was the exclusive hospital sponsor of the 2021 virtual and in-person New York metropolitan area walks. We were so grateful to team up with Northwell Health for the third year to support pancreatic cancer patients.
$1.125m
Raised Through 170 Community Activities

COMMUNITY ACTIVITIES
Lustgarten event organizers and donors provide people affected by pancreatic cancer a voice and a platform to create hope, together.

Each of the community activities below raised at least $1,000.

ATHLETICS
Big Deb Classic Fishing Tournament in Memory of Deborah Bailey
Canter for the Cure in Memory of Arlene Bates Toyne
Diamond Hill CrossFit Fundraiser
Port Jefferson Yacht Club Foundation Village Cup Regatta
Steve Rickert Memorial Shoot
Ride for Research ATV Rally
Sk8 to ElimIn8 Cancer
S.O.A.R. in Memory of Dr. Johnny V. Baylor
St. Louis Squash in Memory of Mike Donio
Yoga Amongst Friends in Memory of Candy Stevens

ENDURANCE
NYC Marathon–Jack Statfeld and in Memory of Ted Rosenberg

FUNDRAISE YOUR WAY
In Honor of Ed Gauss
In Honor of Rob Gotlin
In Honor of Michelle Gross
In Honor of Lois Harris and Radmila Djordjevic
In Honor of Julie Johnson
In Honor of Annamma Joseph
In Honor of Bubby–Gangadhar Mantravadi
In Honor of Geraldine Martinez
In Honor of Kathy Pasquarette
In Loving Memory of Jeanette Grogan
In Loving Memory of Michael F. Pasquale
In Loving Memory of Joel Sachs and in Honor of Mel Sachs
In Memory of Loretta Battista Buchanan Family in Memory of Larry Neil Buchanan
In Memory of Liliane Cannon
In Memory of Jennifer Casey
In Memory of Rayna Collin
In Memory of Philip D. Cook
In Memory of Jamie Davis
In Memory of Rudy Harris
In Memory of Fred Hauser
In Memory of Anne Hillelsohn
In Memory of Emily Kline and Steve Shapiro
In Memory of our beloved Marlene Kwiatkowski
In Memory of Greg Mayworm
In Memory of Anne McGuinness
Sue Castro in Memory of Elaine McMahon
In Memory of Rick Oliver
In Memory of Liz Tobin
In Memory of James Vandertulip
In Memory of Ken Zaback
Race for Research
Oscar "Ozzie" Snyder Memorial
FCSP Foundation and in Honor of all Patients, their Families and Friends
Grace Wine Fundraiser in Memory of Bruce "Luke" Osborne
Rylan Kerker Fundraiser in Memory of PopPop
Lacey Township Local 238 PBA No Shave November
Maggie's Mask Chains and Bracelets
Mon-Sai Gives to a Cure
No Shave November
Pampered Chef Party in Memory of Charles Esterline
Pine Hills Ladies League Charity Day
Purple Day in Memory of David Stellmack
Purple Pumpkins for Pancreatic Cancer Awareness and Search for a Cure in Memory of Joseph T. Alessi
Raising Hope For Others
Cole Schmitz Community Fundraiser
St. John’s Episcopal Church Harvest Fair
Stone House Nursery Father’s Day Fundraiser
Thirty-One Gift Fundraiser
Trulieve PC Awareness Month Fundraiser
Eric Van Straten Fundraiser

SOCIAL
Alpha Zeta Omega Fundraiser
Americana Manhasset Champions for Charity
The Art of Love Benefitting Pancreatic Cancer Research
Bike for Bar Mitzvah Fundraiser–in Memory of Grandma Maxine
Boston Scientific No Shave November Breathwork Class with Ryan Kennedy
Bring A Buck
Byram Hills High School Youth Against Cancer
Cocktails for a Cure
In Memory of Joanne Coleman

TRIBUTE
In Honor of Ylisa Kuntz Birthday
In Honor of Lenore Lewis 70th Birthday

WALKS & RUNS
10 Miles for Pop Pop
Scacia Run for Pancreatic Cancer Research at Ohio University
Help Fight Cancer Walk Lake Wallkill
Pound the Pavement for Purple
5K Run/Walk
RMS Walks for HOPE
Run for Research In Memory of Mom
Walk-A-Thon in Memory of Edward Daguerre
Walk for Joseph Gagné
EVENTS

You fuel the research leading to better treatments, earlier detection and more lives saved. We are so grateful.

VIRTUAL HOLIDAY BASH

Thank you to MSG Entertainment and AMC Networks for hosting Lustgarten’s Virtual Holiday Bash, raising more than $532,000 for pancreatic cancer research. Held annually since 2000, the Bash has raised more than $25.5 million for pancreatic cancer research.

TEE’D OFF AT CANCER GOLF TOURNAMENT

The Wallack family, close friends of Marc Lustgarten, honor their friendship and Marc’s memory at their Tee’d Off at Cancer Golf Tournament in Purchase, NY. Held on Sept. 13, 2021, the event raised nearly $138,000 for research; in total, the Wallack family has raised more than $1.7 million through the 11 golf events they’ve organized.

COCKTAILS FOR A CURE

Jessica Newshel, Anne Hamilton and their event committee organized and hosted Cocktails for a Cure on Nov. 5, 2021, at the New Canaan Nature Center in New Canaan, CT. Dedicated to increasing funding for pancreatic cancer research, Jessica, who lost her uncle to pancreatic cancer, and Anne, whose husband is a pancreatic cancer survivor, have hosted this event since 2019.
The financial performance information for FY21 represents the activity of the Foundation for the period from July 1, 2020 through June 30, 2021.

Financial audit in progress at the time of printing. The audited financial statements of the Lustgarten Foundation are available on our website, www.lustgarten.org, or upon request.

100% of donations fund pancreatic cancer research.
The Lustgarten Foundation is grateful for our community’s dedication to transforming pancreatic cancer into a curable disease. Because of your generosity, Lustgarten-funded researchers are advancing research from the laboratory to the clinic and giving patients and their families renewed hope.

FOUNDERS
Bill and Ellen Bell
Cablevision Systems Corporation
Mr. and Mrs. Frederick DeMatteis
Mr. and Mrs. Charles F. Dolan
Mr. and Mrs. James L. Dolan
Mr. and Mrs. Amos B. Hostetter Jr.
Mr. and Mrs. John T. Lockton III
The Lustgarten Family
McMullen Family Foundation
Mr. and Mrs. F. F. Randolph Jr.
Mr. and Mrs. Leonard Tow
Charles B. Wang Foundation

CHAIRMAN’S CIRCLE
$10,000,000–$50,000,000
Cumulative Since Inception
Altice USA Media Solutions
Estate of Mary Brenneisen
Cablevision Systems Corporation
The Walter B. Wriston Fund

CHAIRMAN’S CIRCLE
$1,000,000–$9,999,999
Cumulative Since Inception
AMC Networks
Theodore W. Battmer Family Foundation, Inc.
The Antoinette E. (“Mimi”) & Herman Boehm Foundation
Bristol Myers Squibb
Mark Broxmeyer Memorial Fund
Estate of Roberta Coppola
Creative Bath Products, Inc.
Dolan Family Foundation
KPMG LLP
The Lustgarten Family
MSG Entertainment/MSG Sports
Estate of Maxine Stein-Kohler
Estate of Lucille L. Tirkfield

CHIEF EXECUTIVE’S CIRCLE
$500,000–$999,999
Cumulative Since Inception
The Cornelia T. Bailey Foundation
Estate of Patricia C. Galgan
Gibson, Dunn & Crutcher, LLP
The Stephen and Nancy Grand Philanthropic Fund
Dr. Claude V. Greco Charitable Fund
Estate of Dorothy C. Guida
JPenney
Mr. and Mrs. John T. Lockton III
The Ralph C. Marcove Cancer Research Fund, Inc.
McMullen Family Foundation
News Corporation
Newsday
Northwell Health Cancer Institute Pancreatic Cancer Center
Rolfe Pancreatic Cancer Foundation
Ms. Kathryn Schulberg
The Bern Schwartz Family Foundation
Eleanor Schwartz Charitable Foundation
Sullivan & Cromwell LLP
James S. Swinehart Memorial Fund
Mr. Charles Wang
Karen Zissu-Magidson Memorial Fund

PRESIDENT’S CIRCLE
$100,000–$499,999
Cumulative Since Inception
21st Century Fox
The Mark Abrams Memorial Foundation
Amdocs Broadband Cable & Satellite Division
Frank J. Antun Foundation
Arris
Baldor Specialty Foods Inc.
Estate of Judith Bandel
Bank of America

The Harry T. Barbaris, MD Memorial Fund
Leslie B. Barrett Foundation
Bear Stearns Companies, Inc.
Bill and Ellen Bell
Bethpage Federal Credit Union
Stephen & Mary Birch Foundation
BNP Paribas
Boston Scientific Corporation
Brindell Roberts Gottlieb Trust
Brisbin Brook Beynon, Architects
The Clarissa & Edgar Bronfman Jr. Foundation
The Robert and Marion Schamann Brozowski Foundation
Mr. John F. Campbell
The Richard E. Capri Foundation
Mr. and Mrs. Richard L. Chadakoff
Charter Communications
Cisco Systems, Inc.
Citizens Utilities
Clare Rose Foundation, Inc.
Gail V. Coleman and Kenneth M. Bruntel
Cravath, Swaine & Moore LLP
Croatian American Charitable Foundation
Mrs. Dorothy Daly
Debevoise & Plimpton, LLP
Deer Pond Farm Fund
Deloitte & Touche
Estate of Lynda M. Dembek
DevelopOnBox LLC
Discovery Communications, LLC
Disney and ESPN Media Networks
Ms. Mary C. Dix
The Frank and Adrienne Dobbs Family Fund
The Dozen Dimes Foundation, Inc.
Dr. Joan Egrie
Eli Lilly and Company
The Ergonomic Group
ESPN, Inc.
Fashion Accessories Benefit Ball
FCSP Foundation
Mr. Robert P. Flicker
Forchelli Deegan Terrana LLP
Foundation For A Better World, Inc.
Mr. and Mrs. Ronald Frankel
Mr. and Mrs. Ross Frankel
Frenz For A Cause, Inc.
Frontier Touring
Mr. and Mrs. Ken Fuirst
Estate of Ronald H. Gazzola
Genentech, Inc.
Gerstner Family Foundation
Goldman Sachs
Greater Hartford Community Foundation, Inc.
The Peter Grosslight Memorial Fund
The Robert & Lynne Grossman Family Foundation
Mr. Leo A. Guthart
The Marc Haas Foundation
Barbara J. Hall Trust
Irving Hansen Foundation
The John A. Hartford Foundation, Inc.
Russell & Katherine Hawkenson Foundation
Haymakers for Hope, Inc.
HBO
The Hildgenbrand Family Foundation
HJ Kallkow & Co., LLC
J.T. Hobby Jr. Endowment Fund
Hope Foundation
Mr. and Mrs. Amos B. Hostetter Jr.
Estate of Stefi Huber
Hughes Hubbard & Reed LLP
Laura and Brian Hull
ImClone Systems Incorporated
Estate of Michael Inden
Ipsen Biopharmaceuticals, Inc.
The William H. Isacoff, MD Research Foundation
Jenner & Block LLP
Jones Day
Douglas Jones Trust
JP Morgan Chase
The Kalaydjian Family
Kansys, Inc.
Kauff McGuire & Margolis LLP
Kelley Drye & Warren, LLP
Mr. Kerry J. Kirby
Neil M. Klatskin Foundation, Inc.
Las Vegas Sands Corp.
The Lefkofsky Foundation
Ms. Pearl A. Lemieux
Ruth and David Levine
Estate of Laurie Lima
Loeb & Loeb LLP
Dr. Edward F. Loeb and Family
The Mancheski Foundation, Inc.
Mr. and Mrs. Bruce Martin
The McAdam Family Foundation
Merrill Lynch
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Miramax Films
Morgan, Lewis & Bockius LLP
Morgan Stanley
MTV Networks, Inc.
NBA Cares
NBC Universal
The Benjamin Neuhausen Fund for Pancreatic Cancer Research
Nokia Siemens Networks
Ms. Susan G. Oberstein
George L. Ohrstrom Jr. Foundation
OSI Foundation
Paul Hastings
Paul, Weiss, Rifkind, Wharton & Garrison LLP
Estate of Robert F. Penardi
Mr. Robert F. Penardi
The Perelman Family Foundation, Inc.
Petersen Family Fund at the East Bay Community Foundation
Pharmacia & Upjohn Co.
PJT Partners
Port Jefferson Yacht Club Foundation
Pound The Pavement for Purple 5K Run/Walk
Mrs. Richardson Pratt, Jr.
Mrs. F. F. Randolph, Jr.
Estate of Suzanne Rapier
Rensselaer Honda Tom Gorman Memorial Golf Outing
Mr. and Mrs. Peter C. Richardson
Road to Market LTD
Estate of Marie C. Rolla
Ropes & Gray LLP
The Gloria J. Rosenthal Memorial Fund
Jeffrey Rosenzweig Foundation
For Pancreatic Cancer Research
Estate of John A. Ryvik
Mr. and Mrs. David E. Salmanson
Samsung
Barbara Mantoni Santaniello Research Fund Inc.
The Schwartz Family Foundation
Virginia Grande Schwenk
Scientific-Atlanta, Inc.
Greg and Lynda Seck
Howard Shapiro Memorial Fund
Shearman & Sterling LLP
Shostak Charitable Fund
Showtime Networks, Inc.
Mr. Adam Silver
Sloane & Company
Estate of John P. Smith
The Spionkop Charitable Trust
The Bernice and Milton Stern Foundation
Sun Microsystems
Anne & John Tatta Family Foundation
Thomasville Home Furnishings Metro NY
Time Warner, Inc.
Tom's Cure Pancreatic Cancer Foundation
Mr. Leonard Tow
Turner Broadcasting Systems, Inc.
UBS Financial Services, Inc.
Mr. and Mrs. Mark Udell of London Jewelers
Verizon Communications
Linda J. Verville Cancer Research Foundation
Viacom
Wasily Family Foundation
The Weinstein Company
West New York Restoration of CT, Inc.
John Alexander Wilkins III Memorial Fund
Willkie, Farr & Gallagher, LLP
Estate of Florence E. Wilson
WLNY TV 10/55
WME
Hope and Gavin Wolfe
Suzanne and Bob Wright

FY 2021

This listing reflects gifts received from July 1, 2020-June 30, 2021. Donations of $1,000-$4,999 are listed on our website, Lustgarten.org.

DIAMOND CIRCLE
$100,000-$999,999
The Cornelia T. Bailey Foundation
Bristol Myers Squibb
Gail V. Coleman and Kenneth M. Bruntel
The Dozen Dimes Foundation, Inc.
FCSP Foundation
The Stephen and Nancy Grand Philanthropic Fund
Dr. Claude V. Greco Charitable Fund
Douglas Jones Trust
The McAdam Family Foundation
Northwell Health Cancer Institute
Pancreatic Cancer Center
Petersen Family Fund at the East Bay Community Foundation
Ms. Kathryn Schulberg
The Bern Schwartz Family Foundation
Eleanor Schwartz Charitable Foundation
GOLD CIRCLE
$50,000–$99,999
AMC Networks
Joseph Arena and Dr. Thomas D’Eletto Charitable Fund
Mark Broxmeyer Memorial Fund
Mr. Robert P. Flicker
Gibson, Dunn & Crutcher, LLP
Irving Hansen Foundation
Ipsen Biopharmaceuticals, Inc.
Johnson Charitable Trust at the request of Sandy and Steve Waters, Tara and James Waters, and Anne and Jon Enberg
Ms. Pearl A. Lemieux
Ruth and David Levine
The Marilyn Lichtman Foundation
The Ralph C. Marcove Cancer Research Foundation, Inc.
MSG Entertainment/MSG Sports
Mr. and Mrs. Ronald Frankel
Mr. and Mrs. Ross Frankel
Mr. and Mrs. Ken Fuirst
Greater Hartford Community Foundation, Inc.
Ms. Inge Horn
Deanne Keim Memorial Fund Inc.
The Kessler Family Foundation
Las Vegas Sands Corp.
Mrs. Judith A. Lund
The Lustgarten Family
The Mancheski Foundation, Inc.
NBA Cares
Michael F. Pasquale Memorial Fund
Mr. Thomas C. Putz
Mr. and Mrs. Peter C. Richardson
The Gloria J. Rosenthal Memorial Fund
David M. Seiden Memorial Fund
Shostak Charitable Fund
St. Francis Hospital
James M. and Margaret V. Stine Foundation
James S. Swinehart Memorial Fund
Dr. and Mrs. Robert F. Vizza
Karen Zissu-Majidson Memorial Fund

BRONZE CIRCLE
$10,000–$24,999
Mr. Howard Adler
Akin Gump Strauss Hauer & Feld, LLP
George J. Argeris Trust
The Elias, Genevieve and Georgianna Atol Charitable Trust
Alan August
Bahnik Foundation, Inc.
Bank of America
Mrs. Evelyn Barrow
The Bauer Charitable Remainder Trust
Bill and Ellen Bell
Mrs. Linda K. Berger
Richard Bernstein Revocable Trust
Bethpage Federal Credit Union
Bijjar Family Foundation
Bonner Family Private Foundation, Inc.
Boston Scientific Corporation
Boyle Family Foundation
The Clarissa & Edgar Bronfman Jr. Foundation
The Robert C. Brooks Revocable Trust
The Robert and Marion Schamann Brozowski Foundation
Mr. Salvatore M. Cali
Mr. John F. Campbell
Mrs. Carolann C. Catalogne
Mr. and Mrs. Richard L. Chadakoff
Mr. and Mrs. Laurence J. Cohen
Robert Colleran Charitable Gift Fund
Cravath, Swaine & Moore LLP
Mr. J. Keith Davidson
Ms. Melodee R. Davis
The Denver Foundation
Ms. Mary C. Dix
Dolan Family Fund at the Cleveland Foundation
Mr. Joshua E. Dubin
Dr. Joan Egrie
Marvin and Barbara Eisenstadt Charitable Foundation
Mrs. Daryl Elliott
Ms. Rhonda Ellison
Elmwood Park Volunteer Ambulance
Epic Charitable Fund
Joan C. Evans Charitable Fund
Mr. and Mrs. Eugene F. Fama
Eric Felman Memorial Foundation, Inc.
Fifth Avenue of L.I. Realty Association
Anthony Ford Charitable Foundation

SILVER CIRCLE
$25,000–$49,999
The Warren Alpert Foundation
Leslie B. Barrett Foundation
The Robert J. Bauer Family Foundation
Robert Black Charitable Foundation
The Antoinette E. (“Mimi”) & Herman Boehm Foundation
The Richard E. Capri Foundation
Charter Communications
Mr. and Mrs. Ronald Frankel
Mr. and Mrs. Ross Frankel
Mr. and Mrs. Ken Fuirst
Greater Hartford Community Foundation, Inc.
Mrs. Inge Horn
Deanne Keim Memorial Fund Inc.
The Kessler Family Foundation
Las Vegas Sands Corp.
Mrs. Judith A. Lund
The Lustgarten Family
The Mancheski Foundation, Inc.
NBA Cares
Michael F. Pasquale Memorial Fund
Mr. Thomas C. Putz
Mr. and Mrs. Peter C. Richardson
The Gloria J. Rosenthal Memorial Fund
David M. Seiden Memorial Fund
Shostak Charitable Fund
St. Francis Hospital
James M. and Margaret V. Stine Foundation
Mrs. Helene Fortunoff and Mr. Robert Grossman
Jennie Fortunoff and Andrew Chonofsky
Mr. Alan M. Fressle and Ms. Angela Fressle
Mrs. Sharon Fressle
Mrs. Gail P. Gamboni
Ms. Rita Garland
The Gay Libertarian Fund
Gettry Marcus CPA, P.C.
The Peter Grosslight Memorial Fund
Mrs. Rona M. Guidone
Mr. Brett Harris
Mr. Roger Hathaway
The Hildenhbrand Family Foundation
J.T. Hobby Jr. Endowment Fund
Laura and Brian Hull
Mr. Michael Iacavone
Ms. Jacqueline Jackson
JP Morgan Chase
Mr. and Mrs. Michael Kabat
Kauff McGuire & Margolis LLP
Kay Family Foundation, Inc.
Mr. and Mrs. William H. Kleh
Mr. Howard M. Krams
Ms. Laura Landau
Mr. John Laxmi and Mrs. Diane Laxmi
Dr. Catherine Lee
Mark and Gayle Lerch Family Foundation
Dr. Edward F. Loeb and Family
Mr. and Mrs. Andrew Lustgarten
Ms. Carin Mack
Ms. Sheila Mahony and Mr. Chuck Riggs
Mrs. Charmaine Malachinski
Ms. Leslie Maltz
Mr. Robert F. Mancuso
Ms. Donna J. Matson and Mr. Bob Carpenter
McMullen Family Foundation
Memorial Cancer Institute
Mrs. Diane Miller and Family
Ms. Jo Ellen Moore
Mr. Joseph Moretti
Morgan, Lewis & Bockius LLP
Mr. Rafal Murczek
Mrs. Carol Nick
Northside Hospital
Novocure
Oak Foundation USA
Mrs. Angela Osborne
Norma Pace Foundation
The Paraschac Family
Mr. Kirk Pasich
PGA Tour, Inc.
Mr. James Pisanelli
Port Jefferson Yacht Club Foundation
Pound The Pavement for Purple 5K Run/Walk
Proskauer Rose LLP
The Paul Rand Charitable Trust
Mr. and Mrs. Benjamin Rosenberg
Ms. Laura Rossi
Mr. Harvey Rudman
Maurice and Lena Russo Family Foundation
SAS Foundation for Cancer Research, Inc.
Mr. Alan D. Schwartz
Ms. Judith Siegfried
Mr. Harvey Rudman
Maurice and Lena Russo Family Foundation
SAS Foundation for Cancer Research, Inc.
Mr. Alan D. Schwartz
Ms. Judith Siegfried
Mr. Adam Silver
Arnold Simonsen Family Charitable Foundation, Inc.
Ms. Susan B. Stearns
Mr. Robert Sturgis
The Sunshine Foundation
Anne & John Tatta Family Foundation
Dwight D. Taylor Charitable Fund
Tom’s Cure Pancreatic Cancer Foundation
Truileve, Inc.
Mr. Richard B. Tuunan
The Sunshine Foundation
Anne & John Tatta Family Foundation
Dwight D. Taylor Charitable Fund
Tom’s Cure Pancreatic Cancer Foundation
Truileve, Inc.
Mr. Richard B. Tuunan
Tuner Construction Company
UBS
United Radio, Inc.
U.S. Bank
Ms. Meredith Vieira and Mr. Richard Cohen
The Wallach Family
Mr. and Mrs. Timothy J. Walsh
Charles B. Wang Foundation
Webster Bank
Wells Fargo Bank
The West Endowment
Mr. Lewis Wiener
Willis Towers Watson
Winfield Foundation
Hope and Gavin Wolfe
Mr. and Mrs. Chuck Yablon
Mr. Mike D. Yantis and Family
Mr. and Mrs. David Yarnold
Stanley Shalom Zielony Foundation
BENEFACTOR CIRCLE
$5,000–$9,999
Mr. and Mrs. James Albers
Mr. Sig Anderman
Irv & Bee Apatoff Foundation, Inc.
Gene Armatorio Family Charitable Fund
Aurora Police Department
Ms. Sharon Baldasare
Baldor Specialty Foods Inc.
The Beautiful C Foundation
Ms. Elaine F. Bentley
Abbe Berman Foundation Trust
Berro Family Foundation, Inc.
Ms. Phyllis Bilus
Blake, Cassels & Graydon LLP
Mr. and Mrs. Richard Blomquist
Bob Heinmiller A/C, Inc.
Ms. Candice R. Boite
Mr. Peter N. BonTempo Jr.
R. Keith Butterfield Memorial Fund
Mr. and Mrs. Robert K. Butterfield Jr.
Mr. Thomas Caniano
Mr. David Cannon
Mrs. Gabrielle Cioffi
Ms. Alana Clegg
Mrs. Linda Cohen
Ms. Georgia Cooper
Alan and Jane Cornell Family Foundation
Linda M. Cote Charitable Fund
Gary and Laurie Damast
Dana-Farber Cancer Institute
Daniell Family Foundation Inc.
Mr. and Mrs. Thomas F. DeGrazia
Michael and Renee Dernburg
The Frank and Adrienne Dobbs Family Fund
DWB Family Foundation
Edward Darman Co., L.P.
Mr. and Mrs. Tom Edwards
Mrs. Gail R. Eisenberg
Elevation Oncology, Inc.
The Ergonomic Group
Ernst & Young
Erytech
Lydia K. Feidler Charitable Trust
The First National Bank of Long Island
First Republic Bank
Wayne S. Flick & William D. Hynes Charitable Gift Fund
Mr. Marvin A. Flood
Floors for the Cure Foundation
Fox Ad Sales
Mr. Charles Frankel
Stuart and Nancy Friedell Family Foundation
Ms. Patricia J. Galloway
Ms. Rosalie H. Gensler and Mr. Steven Schwartz
Mr. Joshua Gillon and Family
Mr. and Mrs. Mitchell Ginsburg
Gleason Family Foundation, Inc.
Mrs. Sherry Gold
Ms. Marcie Goldstein
Good Hope Foundation
Mr. Sheldon P. Gordon
Dr. Peter M. Gotlieb and Ms. Diane Gotlieb
Mr. Todd Greenberg
The Paul B. Greetin and Beryl S. Greetin Foundation, Inc.
Ms. Jane Griffith
Ms. Laura Grim
Gross Family Fund
Mr. and Mrs. Nachum Gross
GS Humane Corp.
Barbara J. Hall Trust
Ms. Elisabeth R. Hardin
Hearst
The Per and Astrid Heidenreich Family Foundation
Mr. Merrit Heminway
Mr. Paul H. Herbert
Mrs. Sylvia Jacobs and Family
Joyce and James Jenkins
J.T. Magen & Company, Inc.
Mrs. Louise Kaminow
Mr. Warren Kaplan
Lawrence Katzman Charitable Foundation Inc.
Dr. Rebecca L. Keim and Mr. Nathan T. Pruitt
The Kelly Family Foundation
Christopher and Tiffany Kete
Kieffer Family Fund
King & Spalding LLP
Mr. Kerry J. Kirby
Mr. and Ms. Kenneth H. Klein
Mrs. Carolyn Kline
Harold Kramer Foundation
Mr. Phillip Krejci
Mrs. Joan B. Lane
Lawton Adams Construction
Ms. Marianne Lazarou-Benjamin
Ms. Cheryl Lehman
The Lerner Family Foundation
Mrs. Iris C. Lerner
Charles and Margaret Levin Family Foundation, Inc.
Mr. Michael S. Levine
Thalia and George Liberatos Foundation, Inc.
Mr. and Mrs. Aaron Linsky
Louis and Tobey Lipschitz Charitable Fund
Lott Foundation
Mr. Robert Lourie
Ms. Helen Lowenstein
Mr. Stuart Lubow
Mac Sales Group, Inc.
Mr. and Mrs. Joseph Mancino
Mr. Jonathan Manhan
Marsh & McLennan Agency LLC
Massachusetts Institute of Technology
Mr. Malcolm McCullough
Ms. Jorden McDowell
The Virginia Metzler Family Charitable Foundation
Ms. Phyllis W. Miller
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Ms. Melissa R. Mirabile
The Moloney Family Foundation
Mr. Thomas F. Monahan
Mountain Ash Properties, LLC
Bernadette and Michael Olsen
Omegaphi
Mr. Bas Ording
Oresky & Associates, PLLC
Mrs. Erika L. Padgett and Mr. Tom Padgett
MONTHLY DONORS FUEL PROGRESS!

Partners in Progress are dedicated supporters who provide monthly gifts to the Lustgarten Foundation. These regular contributions drive new breakthroughs in early detection, drug development and personalized medicine, giving patients the best chance for survival and quality of life. To join Partners in Progress, please call 866.789.1000 or visit Lustgarten.org/monthly.
# Lustgarten Leadership

## Board of Directors

<table>
<thead>
<tr>
<th>Name</th>
<th>Title and Role</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Andrew Lustgarten</strong></td>
<td>Chairman, Lustgarten Foundation; President, MSG Entertainment; President &amp; CEO, MSG Sports</td>
</tr>
<tr>
<td><strong>James L. Dolan</strong></td>
<td>Vice Chairman, Lustgarten Foundation; Executive Chairman &amp; CEO, MSG Entertainment; Executive Chairman, MSG Sports and AMC Networks</td>
</tr>
<tr>
<td><strong>Adam Silver</strong></td>
<td>Vice Chairman, Lustgarten Foundation; Commissioner, National Basketball Association</td>
</tr>
<tr>
<td><strong>Charles F. Dolan</strong></td>
<td>Chairman Emeritus, Lustgarten Foundation; Chairman Emeritus, AMC Networks; Former Chairman, Cablevision Systems Corporation</td>
</tr>
<tr>
<td><strong>Robert F. Vizza, PhD</strong></td>
<td>Chairman Emeritus, Lustgarten Foundation</td>
</tr>
<tr>
<td><strong>William Bell</strong></td>
<td>Treasurer, Lustgarten Foundation; Former Vice Chairman, Cablevision Systems Corporation</td>
</tr>
<tr>
<td><strong>Sommer Bazuro, PhD</strong></td>
<td>Chief Medical Officer, FCB Health New York</td>
</tr>
<tr>
<td><strong>John Cobb</strong></td>
<td>Partner, Paul Hastings</td>
</tr>
<tr>
<td><strong>Jessica Lustgarten Courtemanche</strong></td>
<td>Vice President/Director, Data and Analysis, DigitasLBi North America</td>
</tr>
<tr>
<td><strong>Quentin Dolan</strong></td>
<td>Director, MSG Networks</td>
</tr>
<tr>
<td><strong>Jennie Fortunoff</strong></td>
<td>Principal, Esterow Events &amp; Consulting, Inc.</td>
</tr>
<tr>
<td><strong>Kenneth Goodman, MD</strong></td>
<td>Former Director, Department of Radiology and Attending Physician, St. Francis Hospital</td>
</tr>
<tr>
<td><strong>Kerri Kaplan</strong></td>
<td>President, Lustgarten Foundation (term expired 6/30/21)</td>
</tr>
<tr>
<td><strong>Marcia Lustgarten</strong></td>
<td>Former Director, Optimum Community, Cablevision Systems Corporation</td>
</tr>
<tr>
<td><strong>Sheila Mahony</strong></td>
<td>Former Executive Vice President, Communication, Government and Public Affairs, Cablevision Systems Corporation</td>
</tr>
<tr>
<td><strong>Charles R. Schueler</strong></td>
<td>Former Executive Vice President, Media and Community Relations, Cablevision Systems Corporation</td>
</tr>
<tr>
<td><strong>Willa Shalit</strong></td>
<td>Co-Founder and Principal, RTM Limited; Co-Founder, Let’s Win! Pancreatic Cancer Foundation</td>
</tr>
<tr>
<td><strong>Linda Tantawi</strong></td>
<td>CEO, Lustgarten Foundation</td>
</tr>
<tr>
<td><strong>David Tuveson, MD, PhD</strong></td>
<td>Chief Scientist, Lustgarten Foundation; Cold Spring Harbor Laboratory Cancer Center</td>
</tr>
<tr>
<td><strong>Elizabeth M. Jaffee, MD</strong></td>
<td>Chief Medical Advisor, Lustgarten Foundation; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</td>
</tr>
<tr>
<td><strong>Peter Allen, MD</strong></td>
<td>Duke University</td>
</tr>
<tr>
<td><strong>Dafna Bar-Sagi, PhD</strong></td>
<td>NYU Langone</td>
</tr>
<tr>
<td><strong>Luis Diaz, MD</strong></td>
<td>Memorial Sloan Kettering Cancer Center</td>
</tr>
<tr>
<td><strong>Ted Hong, MD</strong></td>
<td>Dana-Farber Cancer Institute/Harvard Cancer Center</td>
</tr>
<tr>
<td><strong>Tyler Jacks, PhD</strong></td>
<td>Koch Institute, MIT</td>
</tr>
<tr>
<td><strong>Reuben Shaw, PhD</strong></td>
<td>Salk Institute</td>
</tr>
<tr>
<td><strong>Selwyn Vickers, MD</strong></td>
<td>University of Alabama at Birmingham</td>
</tr>
<tr>
<td><strong>Bert Vogelstein, MD</strong></td>
<td>The Johns Hopkins Medical School and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</td>
</tr>
<tr>
<td><strong>Jen Jen Yeh, MD</strong></td>
<td>UNC School of Medicine</td>
</tr>
</tbody>
</table>

## Scientific Advisory Board

- **David Tuveson, MD, PhD**
- **Elizabeth M. Jaffee, MD**
- **Peter Allen, MD**
- **Dafna Bar-Sagi, PhD**
- **Luis Diaz, MD**
- **Ted Hong, MD**
- **Tyler Jacks, PhD**
- **Reuben Shaw, PhD**
- **Selwyn Vickers, MD**
- **Bert Vogelstein, MD**

## Corporate Advisory Board, Emeritus

- **The Honorable Jimmy Carter**
- **Frank A. Bennack, Jr.**
- **Barry Diller**
- **John S. Hendricks**
- **Mel Karmazin**
- **Gerald M. Levin**
- **John C. Malone**
- **Rupert Murdoch**
- **Tom Rogers**
- **Sir Howard Stringer**

*indicates new member
FOCUSED MISSION

OUR MISSION IS TO CURE PANCREATIC CANCER BY:

Funding scientific and clinical research related to the diagnosis, treatment and prevention of pancreatic cancer;

Providing research information and clinical support services to patients, caregivers and individuals at high risk; and

Increasing public awareness and hope for those dealing with this disease.

The Lustgarten Foundation envisions a world where pancreatic cancer is curable and patients will be treated effectively and enjoy a better quality of life.

100% OF DONATIONS FUND PANCREATIC CANCER RESEARCH.

LUSTGARTEN FOUNDATION

PANCREATIC CANCER RESEARCH

415 Crossways Park Dr., Suite D
Woodbury, NY 11797
516.737.1550
www.lustgarten.org